OSAKA, Japan–(EON: Enhanced Online News)–Takeda Pharmaceutical Company Limited (TOKYO:4502), (“Takeda”) today announced a partnership with the Bill & Melinda Gates Foundation to support global polio eradication in developing countries. With this funding, Takeda will develop, license and supply at least 50 million doses per year of Sabin-strain inactivated poliovirus vaccine (sIPV) to more than 70 developing countries. The vaccine will be manufactured at Takeda’s facility in Hikari, Japan. This effort is aligned with Takeda’s strategy to utilize innovation and partnerships to address critical unmet needs in global public health, and the Sustainable Development Goals adopted by the United Nations in September 2015. read more
Platelet BioGenesis Wins Amgen Golden Ticket For LabCentral
PRNewswire/ — Amgen (NASDAQ: AMGN) and LabCentral announced today that Platelet BioGenesis is an Amgen’s 2016 winner of the highly competitive Golden Ticket award, which underwrites the cost of a lab bench for a Platelet BioGenesis scientist in LabCentral’s open lab for one year. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high-impact life-sciences and biotech startups. As one of LabCentral’s platinum sponsors, Amgen can nominate up to two early-stage companies to take up residence in LabCentral’s Kendall Square facilities in Cambridge, Massachusetts. read more
JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China
GE Healthcare delivers world’s first modular manufacturing solution based on single-use bioprocessing technology in just 18 months
CHALFONT ST. GILES, United Kingdom & WUHAN, China–(BUSINESS WIRE)–JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China today.
Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
- Incyte to Accelerate the Expansion of its European Organization to Optimize the Potential of Future Product Launches in Europe
- ARIAD to Receive $140 Million Upfront Payment, Plus Tiered Royalties on European Sales of Iclusig and Potential Milestones on Future Indications for Iclusig
WILMINGTON, Del. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) today announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations. At the close of the transaction, the companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialize Iclusig® (ponatinib) in Europe and other select countries. read more
Thermo Fisher Scientific Expands Use of Advanced Technologies for Customers in Applied Markets
MUNICH–(BUSINESS WIRE)–Analytica 2016 — Thermo Fisher Scientific Inc., the world leader in serving science, today reinforced its ongoing commitment to help its customers accelerate innovation and enhance productivity. At Analytica the company will showcase new products across its instrument, consumables, software and services portfolio that make advanced analysis more accessible to customers in applied markets. Attendees can experience the company’s depth of capabilities in Hall 1, Booth 101 at the Messe Munchen May 10-13, 2016 during the 25th International Trade Fair for Laboratory Technology, Analysis and Biotechnology and analytica conference.
Cell Therapy Ltd. Grants Japan License To Daiichi Sankyo For Its Heart Regeneration Medicine, Heartcel
CARDIFF, Wales–(BUSINESS WIRE)–Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel™ (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global manufacturing responsibilities. Under the terms of the agreement, CTL receives a £12.5 million upfront licensing fee and additional milestone payments and royalties. read more
People in Sweden, Denmark and Finland with Advanced Liposarcoma Now Able to Access Halaven® (Eribulin), First-ever Treatment to Prolong Overall Survival in Rare and Aggressive Cancer
Halaven® (Eribulin) is now available in Sweden, Denmark and Finland for the treatment of adult patients with unresectable advanced or metastatic liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. The news follows the decision by the European Commission to approve the licence variation to the terms of the Marketing Authorisation for Eribulin on 2 May. Eribulin is the first and only single agent therapy to show a significant survival advantage in this type of soft tissue sarcoma. For more information about Eisai Co., Ltd., please visit http://www.eisai.com.
Zika Mouse Model Using Current Strain Enhances Quest for New Vaccines and Treatments
PRNewswire-USNewswire/ — IIT Research Institute (IITRI) scientists have developed a novel mouse model for Zika infections using the current viral strain responsible for outbreaks in Central and South America, and more than 1000 locally-acquired and imported cases in the U.S. and territories. The Zika mouse model is urgently needed to rapidly test new drugs and vaccines against the same strain associated with microcephaly in newborns. read more
PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved an expansion to the IMBRUVICA® (ibrutinib) U.S. Prescribing Information (PI) based on data supporting its use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Janssen announced today.1 The approved label now includes overall survival (OS) data from the Phase 3 RESONATE™-2 (PCYC-1115) trial in treatment-naïve CLL/SLL patients 65 years or older. The updated label also contains clinical data from the Phase 3 HELIOS (CLL3001) trial investigating the use of IMBRUVICA in combination with bendamustine and rituximab (BR) versus placebo plus BR in patients with relapsed or refractory CLL/SLL. read more
Experimental Therapy Halts Treatment-Resistant Brain Tumors Researchers Report Lab Breakthrough in Human Cells, Mouse Models for High Grade Gliomas
Researchers report in the journal Cancer Cell an experimental therapy that in laboratory tests on human cells and mouse models stops aggressive, treatment-resistant and deadly brain cancers called glioblastoma and high-grade gliomas. A multi-institutional team led by researchers at Cincinnati Children’s Hospital Medical Center publishes their results on May 9. Testing a multi-step therapeutic strategy, the scientists found a way to use a gene therapy to shut down a gene long-implicated in the formation of high-grade gliomas called Olig2. The protein encoded by Olig2 is expressed in the majority of gliomas. Removing the Olig2 gene halts tumor growth, while elimination of Olig2-producing cells blocks tumor formation. read more